Page last updated: 2024-12-06

indicine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

indicine: RN given refers to (1R-(1alpha,7(2R*,3S*),7abeta))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID73614
CHEMBL ID471483
CHEBI ID5897
SCHEMBL ID166614
MeSH IDM0069727

Synonyms (31)

Synonym
nsc-136052
(+)-indicine
nsc136052 ,
retronecine,3s)-2,3-dihydroxy-2-isopropylbutyrate]
butanoic acid,3-dihydroxy-2-(1-methylethyl)-, [(1r,7ar)-2,3,5,7a-tetrahydro-1-hydroxy-1h-pyrrolizin-7-yl]methyl ester, (2r,3s)-
[(1r,7ar)-1-hydroxy-2,3,5,7a-tetrahydro-1h-pyrrolizin-7-yl]methyl (2r,3s)-2,3-dihydroxy-2-isopropylbutanoate
[(1r,7ar)-1-hydroxy-2,3,5,7a-tetrahydro-1h-pyrrolizin-7-yl]methyl (2r,3s)-2,3-dihydroxy-2-(propan-2-yl)butanoate
CHEBI:5897 ,
nsc 136052
2,3-dihydroxy-2-(1-methylethyl)-butanoic acid (2,3,5,7a-tetrahydro-1-hydroxy-1h-pyrrolizin-7-yl) methyl ester
butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, (2,3,5,7a-tetrahydro-1-hydroxy-1h-pyrrolizin-7-yl)methyl ester, (1r-(1a,7(2r*,3s*),7a-beta))-
brn 4324630
indicine
480-82-0
[(7r,8r)-7-hydroxy-5,6,7,8-tetrahydro-3h-pyrrolizin-1-yl]methyl (2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methyl-butanoate
butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, [(1r,7ar)-2,3,5,7a-tetrahydro-1-hydroxy-1h-pyrrolizin-7-yl]methyl ester, (2r,3s)-
NCI60_000822
[(7r,8r)-7-hydroxy-5,6,7,8-tetrahydro-3h-pyrrolizin-1-yl]methyl (2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate
[(1r,7ar)-1-hydroxy-2,3,5,7a-tetrahydro-1h-pyrrolizin-7-yl]methyl(2r,3s)-2,3-dihydroxy-2-isopropylbutanoate
CHEMBL471483
t82sfg1584 ,
unii-t82sfg1584
SCHEMBL166614
SFVVQRJOGUKCEG-XTWPYSKKSA-N
retronecine, 7-((2r,3s)-2,3-dihydroxy-2-isopropylbutyrate)
butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, ((1r,7ar)-2,3,5,7a-tetrahydro-1-hydroxy-1h-pyrrolizin-7-yl)methyl ester, (2r,3s)-
butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, (2,3,5,7a-tetrahydro-1-hydroxy-1h-pyrrolizin-7-yl)methyl ester, (1r-(1.alpha.,7(2r*,3s*),7a.beta.))-
DTXSID60197389
AKOS030242135
Q27106927
FS-6709

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Based on clinical signs of poisoning, serum biochemistry, and histopathological analysis the reduced comfrey extract was more toxic than lycopsamine and intermedine."( The comparative toxicity of a reduced, crude comfrey (Symphytum officinale) alkaloid extract and the pure, comfrey-derived pyrrolizidine alkaloids, lycopsamine and intermedine in chicks (Gallus gallus domesticus).
Brown, AW; Colegate, SM; Gardner, DR; Hall, JO; Knoppel, EL; Panter, KE; Stegelmeier, BL, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" One patient with renal impairment had an abnormally long plasma elimination phase half-life (275 min) and reduced plasma clearance (17 ml/min/m2)."( Pharmacokinetic study of indicine N-oxide in pediatric cancer patients.
Ames, MM; Coccia, PF; Davis, DM; Hughes, CS; Miser, JS; Smithson, WA, 1982
)
0.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
pyrrolizines
carboxylic esterAn ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1871836Antiplatelet aggregation activity in rabbit platelet assessed as reduction in ADP-induced platelet aggregation2022European journal of medicinal chemistry, Jan-15, Volume: 228Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.
AID1871835Antiplatelet activity in platelet (unknown origin) assessed as inhibition of ADP-induced platelet aggregation relative to control2022European journal of medicinal chemistry, Jan-15, Volume: 228Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (21.21)18.7374
1990's2 (6.06)18.2507
2000's11 (33.33)29.6817
2010's10 (30.30)24.3611
2020's3 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.90 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index53.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (97.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]